CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from a Phase I clinical study of CPI-613 for the treatment …
Excerpt from:
Cornerstone Pharmaceuticals to Present CPI-613 Phase I Results at 2013 American Society of Hematology Annual Meeting
CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase …
CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 …
Read more here:
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell …
The Brain & Behavior Research Foundation, an organization dedicated to improving the lives of those with mental illness through the transformative power of neuroscience and psychiatric research, will hold its 25th Annual Mental Health Research Symposium on Friday, October 25th from 9:00 am to 4:30 p.m.
View original post here:
Leading Researchers to Present Cutting-Edge Discoveries at the Brain & Behavior Research Foundation Mental Health …
( Brain & Behavior Research Foundation ) Leading researchers to present cutting-edge discoveries at the Brain & Behavior Research Foundation Mental Health Research Symposium in New York City on Oct.
Follow this link:
Mental Health Research Symposium in New York City on Oct. 25
CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S.
Genes in mitochondria, the “powerhouses” that turn sugar into energy in human cells, shape a person’s risk for heart disease and diabetes, according to a study from researchers at the University of Alabama at Birmingham (UAB).
Link:
DNA link to sugar impact risk for heart disease and diabetes
CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase II clinical …
View original post here:
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome
BILLERICA, Mass., Sept. 23, 2013 /PRNewswire/ — In an invited talk at Europe's 2013 MipTec Conference and Exhibition, Seahorse Bioscience Chief Executive Officer, Jay Teich, will discuss the factors that …
See the original post:
Seahorse Bioscience – Growing in a World of Budget Constraints
BILLERICA, Mass., Aug. 22, 2013 /PRNewswire/ — Seahorse Bioscience will provide the Cancer Research UK Beatson Institute with its novel XF technology, which measures cell metabolism, to boost research …
Taken from:
Seahorse Bioscience and the Cancer Research UK Beatson Institute Team Up Against Cancer